| Title |
A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L)
|
|---|---|
| Published in |
Clinical Cancer Research, December 2021
|
| DOI | 10.1158/1078-0432.ccr-21-3194 |
| Pubmed ID | |
| Authors |
Hidetoshi Hayashi, Shunichi Sugawara, Yasushi Fukuda, Daichi Fujimoto, Satoru Miura, Keiichi Ota, Yuichi Ozawa, Satoshi Hara, Junko Tanizaki, Koichi Azuma, Shota Omori, Motoko Tachihara, Kazumi Nishino, Akihiro Bessho, Yasutaka Chiba, Koji Haratani, Kazuko Sakai, Kazuto Nishio, Nobuyuki Yamamoto, Kazuhiko Nakagawa |
X Demographics
The data shown below were collected from the profiles of 40 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 6 | 15% |
| France | 6 | 15% |
| Italy | 2 | 5% |
| Greece | 1 | 3% |
| Singapore | 1 | 3% |
| Brazil | 1 | 3% |
| Georgia | 1 | 3% |
| Mexico | 1 | 3% |
| India | 1 | 3% |
| Other | 2 | 5% |
| Unknown | 18 | 45% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 28 | 70% |
| Practitioners (doctors, other healthcare professionals) | 7 | 18% |
| Scientists | 4 | 10% |
| Science communicators (journalists, bloggers, editors) | 1 | 3% |
Mendeley readers
The data shown below were compiled from readership statistics for 28 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 28 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 4 | 14% |
| Researcher | 3 | 11% |
| Lecturer > Senior Lecturer | 1 | 4% |
| Other | 1 | 4% |
| Student > Doctoral Student | 1 | 4% |
| Other | 3 | 11% |
| Unknown | 15 | 54% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 25% |
| Nursing and Health Professions | 2 | 7% |
| Chemical Engineering | 1 | 4% |
| Business, Management and Accounting | 1 | 4% |
| Unspecified | 1 | 4% |
| Other | 2 | 7% |
| Unknown | 14 | 50% |
Attention Score in Context
This research output has an Altmetric Attention Score of 23. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 November 2023.
All research outputs
#1,616,847
of 25,081,419 outputs
Outputs from Clinical Cancer Research
#1,166
of 13,171 outputs
Outputs of similar age
#38,913
of 515,912 outputs
Outputs of similar age from Clinical Cancer Research
#33
of 168 outputs
Altmetric has tracked 25,081,419 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,171 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.7. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 515,912 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 168 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.